Caroline DePaul's questions to Lexicon Pharmaceuticals Inc (LXRX) leadership • Q2 2025
Question
Caroline DePaul of Citi, on behalf of Yigal Nochomovitz, inquired about partner Novo Nordisk's plans for the Phase 1 study of LX9851 in obesity, specifically asking about potential combinations with GLP-1 agonists.
Answer
SVP & Chief Medical Officer Dr. Craig Granowitz confirmed that discussions with Novo Nordisk align with the market trend toward oral and combination therapies, positioning LX9851 as a strong candidate for use with agents like semaglutide and in triple combinations. CEO Mike Exton added that Novo Nordisk is highly enthusiastic and committed to advancing the program with 'vigor' following the IND filing.